Biosimilars are generic versions of biologics, medicinal products with active drug component being made (or derived) from a living organism. It is complicated and cost intensive to manufacture biologics, and hence regulatory approval of biosimilars is very challenging.
Originally published here.
Advice for Contacting
Engagements: Contractual Consulting, Hourly, Project Based
Contact Mode: LinkedIn or directly message here
Previous Blog Posts on Web
http://l.yimg.com/rt/pps/listbadge_1.8.js
Previous Blog Posts on Twitter
Tweets about “#techlawblog from:rdpatentlawyer”
This is not a legal advice: Disclaimer, Non-Solicitation & Liability
Visit Technology Law Business Blog’s profile on Pinterest.//assets.pinterest.com/js/pinit.js
